ClinicalTrials.gg
RecruitingNCT05348564Updated Apr 14, 2026

Comparing Direct vs Indirect Methods for Cascade Screening

An interventional study of Direct contact of family members for cascade screening of relevant variants in Long QT Syndrome, Familial Hypercholesterolemia and Ethics, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.

Planned enrollment
3rd of 28
200 · median 44
Started
2023
with 2 others
No phase
8 of 44
2 open now
Registered
39th of 44
by date
Lead sponsor
2 of 44
University of Maryland, Baltimore

Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 3rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 39th registered.

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

Browse Long QT Syndrome studies →

Open to participants now

7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Long QT Syndrome with a site in United States, or all of them as a file.
02

Study summary

An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.

Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.

Read the detailed description

Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.

Aim 1:

Aim 1 will assess efficacy of the approaches on uptake of cascade screening. The primary outcome will assess uptake of cascade screening among all first-degree relatives of the probands. We will compare the proportion first-degree relatives who undergo screening out of all eligible relatives in the direct vs indirect arms of the study. Secondary outcomes will asses rate of detection of new cases among all first degree family members. We will have good power to detect a clinically meaningful difference of 15% between he direct and indirect arms of the study.

These cascade screening efficacy endpoints address the question of whether contacting family members for probands improves the uptake of testing among family members.

Aim 2:

Aim 2 will assess patient-centered outcomes in both probands and family members that address how the intervention of direct contact of family members impacts participants' mental, physical, or psychosocial outcomes. For this aim surveys will be given to the probands and family members approximately one week after contact of family members has occurred and at the end of the study. The secondary outcomes associated with this aim include: perceived alignment of ethical principles, anxiety regarding method of contact, perceived pressure to undergo testing (family members only), and knowledge of disease. We will also assess health behaviors such as taking recommended preventative medications (beta-blockers and statins), lifestyle modifications, and seeing health care providers. These outcomes will be assessed by validated and study-created surveys assessed 1-week post implementation and at the end of study.

These patient-centered outcomes assess the extent to which the intervention allows for autonomous decision making and is associated with acceptable psychosocial outcomes.

Aim 3:

Aim 3 will perform qualitative assessments of the intervention to evaluate implementation outcomes in the direct vs indirect arms of the study. We will include interviews among 15 probands randomized to the direct arm, 15 probands randomized to the indirect arm, 15 family members who undergo cascade screening from the direct arm (carriers and non-carriers), 15 family members who undergo cascade screening from the indirect arm (carriers and non-carriers), and 15 family members who decline cascade testing (from direct arm and from indirect arm but informed by a proband, thus allowing us to invite them to participate). We will also interview study staff to understand facilitators and challenges across patient and organizational factors.

Implementation reach, dosage, and fidelity will be based on proportions and means/standard deviations for relevant quantitative variables (e.g., number of genetic counseling visits scheduled and completed). Outreach approach's acceptability, barriers, and facilitators will be based on descriptive analyses using interview data. Data analyses will be based on a codebook, consensus coding and consensus narrative Qualitative interviews will be transcribed verbatim and analyzed using NVivo 11.0. The research team will conduct standard content analysis and systematic comparison of data between the two intervention groups; acceptability, appropriateness, patterns in facilitators/barriers, implementation quality, and early sustainment.

In sum, these interviews will provide more in-depth understanding of the ethical implications of our intervention and evaluation of the implementation process by relevant stakeholders.

03

Conditions studied

  • Long QT Syndrome
  • Familial Hypercholesterolemia
  • Ethics
  • Genetic Testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Proband Inclusion Criteria:

  • KCNQ1 Thr224Met or APOB R3527Q carrier
  • 18 years or older

Proband Exclusion Criteria:

  • None

Family Inclusion Criteria:

  • 1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier

Family Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Direct contact

    Study team contact of family members

    Behavioral: Direct contact of family members for cascade screening of relevant variants

  • No intervention
    Indirect contact

    Proband initiated contact of family members

Interventions

  • BehavioralDirect contact of family members for cascade screening of relevant variants

    Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.

06

What researchers measure

Primary outcomes

  1. Uptake of cascade screening among all first-degree relatives

    Proportion of first-degree relatives who undergo testing/All eligible first-degree relatives

    Time frame: Through study completion: approximately 4 years

Secondary outcomes

  1. Number of new cases detected among all first-degree family members

    New cases/All eligible first-degree family members

    Time frame: Through study completion: approximately 4 years

  2. Perceived alignment of ethical principles questionnaire

    Among probands and family members

    Time frame: up to 6 months

  3. Anxiety regarding method of contact questionnaire

    Among probands and family members

    Time frame: up to 6 months

  4. Perceived pressure to undergo testing/share health information questionnaire

    Among probands and family members

    Time frame: up to 6 months

  5. Knowledge of disease and variant questionnaire

    Among probands and family members

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.

Of 15 interventional studies with no phase under Long QT Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 27, 2022
StartActual
May 15, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05348564
Responsible party
Amber Beitelshees (Associate Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Apr 27, 2022
Start date
May 15, 2023
Primary completion
Oct 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Amber L Beitelshees, PharmD
Contact
abeitels@som.umaryland.edu
410-706-0118

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion